4cps-009 efficacy, safety and economic impact of vedolizumab in ulcerative colitis and crohn’s disease

BACKGROUND: Treatments for ulcerative colitis (UC) and Crohn’s disease (CD) include conventional agents and tumour necrosis factor-alpha inhibitors (anti-TNFα). A substantial proportion of patients do not respond, are intolerant to both therapies or these drugs are contraindicated. Vedolizumab, a mo...

全面介紹

Na minha lista:
書目詳細資料
發表在:Eur J Hosp Pharm
Main Authors: Goldaracena, J Preciado, Garcia, J Polo, Becerra, JA Illodo, Punset, M Coma, Garrastatxu, I Monteserin, Gaztelu, M de Miguel, Gonzalez, J Fernandez, Fenoll, A Agulló, Lebrero, G Pinilla, del Amo, ME Carrasco, Carricas, M Sarobe
格式: Artigo
語言:Inglês
出版: BMJ Group 2018
主題:
Section 4: Clinical pharmacy services
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535216/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.100
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍